CABP2

Summary

CABP2 (calcium binding protein 2, HGNC:1385) is a protein-coding gene on chromosome 11q13.2, encoding Calcium-binding protein 2 (Q9NPB3). Required for sound encoding at inner hair cells (IHCs) synapses, likely via inhibition of the inactivation of voltage-gated calcium channel of type 1.3 (Cav1.3) in the IHCs.

This gene belongs to a subfamily of calcium binding proteins that share similarity to calmodulin. Like calmodulin, these family members can likely stimulate calmodulin-dependent kinase II and the protein phosphatase calcineurin. Calcium binding proteins are an important component of calcium mediated cellular signal transduction. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 51475 — RefSeq curated summary.

At a glance

• Gene–disease (curated): nonsyndromic genetic hearing loss (Definitive, ClinGen) — +2 more curated relationships
• GWAS associations: 1
• Clinical variants (ClinVar): 143 total — 2 pathogenic, 8 likely-pathogenic
• Phenotypes (HPO): 3
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity no evidence
• MANE Select transcript: NM_016366

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1385
Approved symbol	CABP2
Name	calcium binding protein 2
Location	11q13.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000167791
Ensembl biotype	protein_coding
OMIM	607314
Entrez	51475

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 nonsense_mediated_decay

ENST00000294288, ENST00000353903, ENST00000545205, ENST00000636477

RefSeq mRNA: 2 — MANE Select: NM_016366 NM_001318496, NM_016366

CCDS: CCDS8170

Canonical transcript exons

ENST00000294288 — 7 exons

Exon	Start	End
ENSE00001064172	67522546	67522716
ENSE00002288874	67518912	67519164
ENSE00003475477	67519793	67519940
ENSE00003526118	67520051	67520160
ENSE00003535704	67521025	67521159
ENSE00003580948	67521952	67521982
ENSE00003890089	67523285	67523446

Expression profiles

Bgee: expression breadth broad, 13 present calls, max score 72.32.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0257 / max 16.8273, expressed in 5 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
120951	0.0257	5

Top tissues by expression

249 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	72.32	gold quality
myocardium	UBERON:0002349	62.03	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	61.91	gold quality
periodontal ligament	UBERON:0008266	60.92	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	60.19	gold quality
biceps brachii	UBERON:0001507	59.93	gold quality
nasal cavity epithelium	UBERON:0005384	59.22	gold quality
heart right ventricle	UBERON:0002080	57.89	gold quality
cerebellar vermis	UBERON:0004720	57.37	silver quality
vastus lateralis	UBERON:0001379	56.59	gold quality
quadriceps femoris	UBERON:0001377	56.53	gold quality
cartilage tissue	UBERON:0002418	54.09	gold quality
pigmented layer of retina	UBERON:0001782	54.00	gold quality
esophagus squamous epithelium	UBERON:0006920	53.64	gold quality
middle temporal gyrus	UBERON:0002771	53.56	gold quality
trabecular bone tissue	UBERON:0002483	52.95	gold quality
buccal mucosa cell	CL:0002336	51.54	gold quality
Brodmann (1909) area 23	UBERON:0013554	51.11	gold quality
body of tongue	UBERON:0011876	50.39	gold quality
Brodmann (1909) area 46	UBERON:0006483	50.04	gold quality
seminal vesicle	UBERON:0000998	49.69	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	49.43	silver quality
blood vessel layer	UBERON:0004797	49.29	gold quality
skeletal muscle tissue	UBERON:0001134	49.23	gold quality
choroid plexus epithelium	UBERON:0003911	48.89	gold quality
nephron tubule	UBERON:0001231	48.39	gold quality
pharyngeal mucosa	UBERON:0000355	47.24	gold quality
mammalian vulva	UBERON:0000997	47.23	gold quality
renal glomerulus	UBERON:0000074	46.86	gold quality
metanephric glomerulus	UBERON:0004736	46.77	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-7316	yes	698.32
E-ANND-3	no	1.22

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting CABP2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-3175	99.65	66.30	2031
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-6752-5P	99.59	67.32	1243
HSA-MIR-12131	99.48	68.72	1673
HSA-MIR-4434	99.10	67.01	1984
HSA-MIR-5703	99.10	67.09	2053
HSA-MIR-6830-5P	99.01	68.73	1884
HSA-MIR-561-5P	98.25	68.13	1365
HSA-MIR-6882-3P	98.23	67.01	1119
HSA-MIR-939-5P	97.10	65.80	1579
HSA-MIR-1343-5P	96.48	66.06	1506
HSA-MIR-541-3P	96.07	66.11	1271
HSA-MIR-654-5P	96.07	66.18	1280

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 2)

• Genetic defects in CABP2 cause moderate-to-severe sensorineural hearing impairment. (PMID:22981119)
• Autosomal recessive nonsyndromic hearing impairment in two Finnish families due to the population enriched CABP2 c.637+1G>T variant. (PMID:35150090)

Cross-species orthologs

16 orthologs

Organism	Symbol	Gene ID
danio_rerio	cabp4	ENSDARG00000008866
mus_musculus	Cabp2	ENSMUSG00000024857
rattus_norvegicus	Cabp2	ENSRNOG00000018339
drosophila_melanogaster	TpnC4	FBGN0033027
drosophila_melanogaster	CG13526	FBGN0034774
drosophila_melanogaster	CG5024	FBGN0039373
drosophila_melanogaster	CG17770	FBGN0039374
drosophila_melanogaster	CG30378	FBGN0050378
caenorhabditis_elegans		WBGENE00000285
caenorhabditis_elegans		WBGENE00000287
caenorhabditis_elegans	pat-10	WBGENE00003934
caenorhabditis_elegans		WBGENE00006583
caenorhabditis_elegans		WBGENE00008453
caenorhabditis_elegans	F35C12.3	WBGENE00009408
caenorhabditis_elegans		WBGENE00015264
caenorhabditis_elegans		WBGENE00019352

Paralogs (20): CABP7 (ENSG00000100314), CABP5 (ENSG00000105507), CALML4 (ENSG00000129007), CALM2 (ENSG00000143933), CETN2 (ENSG00000147400), CETN3 (ENSG00000153140), CABP1 (ENSG00000157782), CALM3 (ENSG00000160014), CALML6 (ENSG00000169885), EFCAB3 (ENSG00000172421), EFCAB12 (ENSG00000172771), CABP4 (ENSG00000175544), CETN1 (ENSG00000177143), CALML3 (ENSG00000178363), CALML5 (ENSG00000178372), CALN1 (ENSG00000183166), CALM1 (ENSG00000198668), EFCAB2 (ENSG00000203666), EFCAB7 (ENSG00000203965), EFCAB9 (ENSG00000214360)

Protein

Protein identifiers

Calcium-binding protein 2 — Q9NPB3 (reviewed: Q9NPB3)

All UniProt accessions (3): A0A1B0GW24, Q9NPB3, F5H458

UniProt curated annotations — full annotation on UniProt →

Function. Required for sound encoding at inner hair cells (IHCs) synapses, likely via inhibition of the inactivation of voltage-gated calcium channel of type 1.3 (Cav1.3) in the IHCs. Required for the normal transfer of light signals through the retina.

Subcellular location. Cytoplasm. Perinuclear region. Cell membrane. Golgi apparatus.

Tissue specificity. Retina.

Disease relevance. Deafness, autosomal recessive, 93 (DFNB93) [MIM:614899] A form of non-syndromic deafness characterized by stable, bilateral, symmetric, prelingual moderate to severe deafness. Hearing impairment is slightly more pronounced in the mid-frequencies, resulting in a distinctive shallow U-shaped audiogram. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NPB3-1	L-CaBP2	yes
Q9NPB3-2	S-CaBP2

RefSeq proteins (2): NP_001305425, NP_057450* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR018247	EF_Hand_1_Ca_BS	Binding_site
IPR043582	CaBP1/2/4/5	Family

Pfam: PF13499

UniProt features (26 total): binding site 14, domain 4, sequence variant 2, initiator methionine 1, chain 1, lipid moiety-binding region 1, splice variant 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NPB3-F1	68.93	0.13

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (14): 95; 97; 102; 165; 167; 169; 171; 176; 202; 204; 206; 213 …

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-9662360	Sensory processing of sound by inner hair cells of the cochlea
R-HSA-9659379	Sensory processing of sound
R-HSA-9709957	Sensory Perception

MSigDB gene sets: 68 (showing top): RNGTGGGC_UNKNOWN, GOBP_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS, GOBP_PHOTOTRANSDUCTION, chr11q13, GOBP_SENSORY_PERCEPTION_OF_LIGHT_STIMULUS, GOBP_RESPONSE_TO_RADIATION, GOBP_DETECTION_OF_LIGHT_STIMULUS, GOBP_RESPONSE_TO_ABIOTIC_STIMULUS, GOBP_DETECTION_OF_ABIOTIC_STIMULUS, GOBP_DETECTION_OF_STIMULUS, GOBP_SENSORY_PERCEPTION, NIKOLSKY_BREAST_CANCER_11Q12_Q14_AMPLICON, GOBP_RESPONSE_TO_LIGHT_STIMULUS, AP4_01, NFAT_Q6

GO Biological Process (3): signal transduction (GO:0007165), visual perception (GO:0007601), sensory perception of sound (GO:0007605)

GO Molecular Function (4): calcium channel regulator activity (GO:0005246), calcium ion binding (GO:0005509), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (5): cytoplasm (GO:0005737), Golgi apparatus (GO:0005794), plasma membrane (GO:0005886), perinuclear region of cytoplasm (GO:0048471), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Sensory processing of sound	1
Sensory Perception	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cytoplasm	2
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
sensory perception of light stimulus	1
sensory perception of mechanical stimulus	1
calcium channel activity	1
ion channel regulator activity	1
metal ion binding	1
binding	1
cation binding	1
intracellular anatomical structure	1
endomembrane system	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1669 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CABP2	S100G	P29377	748
CABP2	CACNA1F	O60840	622
CABP2	GRK5	P34947	594
CABP2	CACNA1D	Q01668	554
CABP2	OTOF	Q9HC10	496
CABP2	STRC	Q7RTU9	491
CABP2	SMOC2	Q9H3U7	487
CABP2	GRXCR2	A6NFK2	478
CABP2	OTOG	Q6ZRI0	468
CABP2	PJVK	Q0ZLH3	460
CABP2	OR2T5	Q6IEZ7	447
CABP2	NCS1	P36610	442
CABP2	TMIE	Q8NEW7	433
CABP2	GRXCR1	A8MXD5	426
CABP2	ILDR1	Q86SU0	426

IntAct

110 interactions, top by confidence:

A	B	Type	Score
CABP2	NOP10	psi-mi:“MI:0915”(physical association)	0.560
CABP2	AVPI1	psi-mi:“MI:0915”(physical association)	0.560
CABP2	ADGRF5	psi-mi:“MI:0915”(physical association)	0.560
CABP2	MXRA8	psi-mi:“MI:0915”(physical association)	0.560
CABP2	COA6	psi-mi:“MI:0915”(physical association)	0.560
CABP2		psi-mi:“MI:0915”(physical association)	0.560
CABP2	ZNF785	psi-mi:“MI:0915”(physical association)	0.560
CABP2	ZNF140	psi-mi:“MI:0915”(physical association)	0.560
CABP2	NME4	psi-mi:“MI:0915”(physical association)	0.560
CABP2	C22orf39	psi-mi:“MI:0915”(physical association)	0.560
HOXD12	CABP2	psi-mi:“MI:0915”(physical association)	0.560
EFHC2	CABP2	psi-mi:“MI:0915”(physical association)	0.560
	CABP2	psi-mi:“MI:0915”(physical association)	0.560
CARD9	CABP2	psi-mi:“MI:0915”(physical association)	0.560
GOLGA6L9	CABP2	psi-mi:“MI:0915”(physical association)	0.560
HOOK2	CABP2	psi-mi:“MI:0915”(physical association)	0.560
UNKL	CABP2	psi-mi:“MI:0915”(physical association)	0.560
THAP6	CABP2	psi-mi:“MI:0915”(physical association)	0.560
ZNF57	CABP2	psi-mi:“MI:0915”(physical association)	0.560
AVPI1	CABP2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (61): CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid), CABP2 (Two-hybrid)

ESM2 similar proteins: A4Q9F3, A8IHN8, D3YYI7, M0R7T9, O09112, O60347, O88751, P51509, Q09YL6, Q0IHH1, Q13202, Q13505, Q14190, Q147X3, Q17QD9, Q3TZ87, Q3UPL5, Q3V1H9, Q5TGI4, Q5VUJ9, Q5VV17, Q5XI57, Q61079, Q6A039, Q6PDS0, Q6ZVT0, Q7Z7K6, Q80UW0, Q86YJ5, Q8C4U2, Q8CES0, Q8N554, Q8N8J7, Q8TC41, Q8TDR2, Q8WWW0, Q96AQ8, Q96ET8, Q96KN8, Q96MM7

Diamond homologs: A8CEP3, D2DGW3, O16305, O60041, O88751, O94739, O96102, P02585, P02586, P02587, P02588, P02589, P02597, P02598, P02599, P04464, P05419, P05933, P06707, P06708, P06787, P07463, P10246, P11118, P11120, P11121, P15094, P15159, P18061, P20801, P23286, P24044, P25071, P27165, P27166, P29290, P29291, P47947, P47948, P47949

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

143 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	8
Uncertain significance	67
Likely benign	47
Benign	9

Top pathogenic / likely-pathogenic (10)

Variant ID	HGVS	Classification
3340148	NM_016366.3(CABP2):c.274C>T (p.Arg92Ter)	Pathogenic
917515	NM_016366.3(CABP2):c.232G>A (p.Glu78Lys)	Pathogenic
1324001	NM_016366.3(CABP2):c.482del (p.Phe161fs)	Likely pathogenic
1698683	NM_016366.3(CABP2):c.490-8C>A	Likely pathogenic
2057154	NM_016366.3(CABP2):c.42+1G>C	Likely pathogenic
2664943	NM_016366.3(CABP2):c.60C>A (p.Leu20=)	Likely pathogenic
2895007	NM_016366.3(CABP2):c.213+1G>A	Likely pathogenic
3898887	NM_016366.3(CABP2):c.547del (p.Ala183fs)	Likely pathogenic
4684997	NM_016366.3(CABP2):c.245-1G>A	Likely pathogenic
817309	NM_016366.2(CABP2):c.638_639delAG	Likely pathogenic

SpliceAI

1316 predictions. Top by Δscore:

Variant	Effect	Δscore
11:67519831:T:TA	donor_gain	1.0000
11:67521023:A:AC	donor_gain	1.0000
11:67521024:C:CC	donor_gain	1.0000
11:67521158:CT:C	acceptor_gain	1.0000
11:67521160:C:CC	acceptor_gain	1.0000
11:67519335:T:C	acceptor_gain	0.9900
11:67520052:T:TA	donor_gain	0.9900
11:67520053:C:A	donor_gain	0.9900
11:67520159:ACC:A	acceptor_loss	0.9900
11:67520162:T:A	acceptor_loss	0.9900
11:67521024:CTG:C	donor_gain	0.9900
11:67521024:CTGA:C	donor_gain	0.9900
11:67521024:CTGAT:C	donor_gain	0.9900
11:67521155:CAGCT:C	acceptor_gain	0.9900
11:67521156:A:T	acceptor_gain	0.9900
11:67521156:AGCT:A	acceptor_gain	0.9900
11:67521159:TC:T	acceptor_loss	0.9900
11:67521161:T:C	acceptor_loss	0.9900
11:67522541:CATA:C	donor_gain	0.9900
11:67522544:A:AC	donor_gain	0.9900
11:67522545:C:CC	donor_gain	0.9900
11:67519335:T:TC	acceptor_gain	0.9800
11:67519743:T:C	donor_gain	0.9800
11:67519941:C:CC	acceptor_gain	0.9800
11:67520158:CAC:C	acceptor_gain	0.9800
11:67520171:C:T	acceptor_gain	0.9800
11:67521021:ATAC:A	donor_loss	0.9800
11:67521022:TA:T	donor_loss	0.9800
11:67521164:C:CT	acceptor_gain	0.9800
11:67522540:A:AC	donor_gain	0.9800

AlphaMissense

1432 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:67521048:A:G	L119P	0.998
11:67521063:G:T	P114H	0.998
11:67521134:A:C	F90L	0.998
11:67521134:A:T	F90L	0.998
11:67521136:A:G	F90L	0.998
11:67521143:G:C	F87L	0.998
11:67521143:G:T	F87L	0.998
11:67521145:A:G	F87L	0.998
11:67519915:A:G	I172T	0.997
11:67520057:G:C	F161L	0.997
11:67520057:G:T	F161L	0.997
11:67520059:A:G	F161L	0.997
11:67520133:A:G	F136S	0.997
11:67521144:A:G	F87S	0.997
11:67519160:A:C	F214L	0.996
11:67519160:A:T	F214L	0.996
11:67519162:A:G	F214L	0.996
11:67519915:A:T	I172N	0.996
11:67520058:A:G	F161S	0.996
11:67520124:A:G	L139P	0.996
11:67520132:G:C	F136L	0.996
11:67520132:G:T	F136L	0.996
11:67520134:A:G	F136L	0.996
11:67521063:G:C	P114R	0.996
11:67521081:C:G	R108P	0.996
11:67521111:A:T	I98N	0.996
11:67521156:A:G	L83P	0.996
11:67519900:A:G	L177P	0.995
11:67520070:A:G	L157P	0.995
11:67521064:G:A	P114S	0.995

dbSNP variants (sampled 300 via entrez): RS1000010545 (11:67521486 A>T), RS1000600618 (11:67525250 C>A), RS1000908049 (11:67525411 G>A), RS1002203521 (11:67518551 C>G,T), RS1002622086 (11:67522928 C>T), RS1002821097 (11:67521282 C>T), RS1002980284 (11:67523164 C>T), RS1003831530 (11:67524782 T>C), RS1003967721 (11:67523715 G>A), RS1004170605 (11:67524181 C>T), RS1004474836 (11:67518578 G>A), RS1005009026 (11:67521892 A>C,T), RS1005585326 (11:67523108 C>T), RS1006122126 (11:67519724 C>G), RS1006364915 (11:67524556 TC>T)

Disease associations

OMIM: gene MIM:607314 | disease phenotypes: MIM:614899, MIM:209850, MIM:220290, MIM:607197

GenCC curated gene-disease

Disease	Classification	Inheritance
nonsyndromic genetic hearing loss	Definitive	Autosomal recessive
autosomal recessive nonsyndromic hearing loss 93	Strong	Autosomal recessive
hearing loss, autosomal recessive	Supportive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
nonsyndromic genetic hearing loss	Definitive	AR

Mondo (5): hearing loss disorder (MONDO:0005365), autosomal recessive nonsyndromic hearing loss 93 (MONDO:0013963), autism (MONDO:0005260), hearing loss, autosomal recessive (MONDO:0019588), nonsyndromic genetic hearing loss (MONDO:0019497)

Orphanet (3): Rare autosomal recessive non-syndromic sensorineural deafness type DFNB (Orphanet:90636), Rare autosomal dominant non-syndromic sensorineural deafness type DFNA (Orphanet:90635), Rare non-syndromic genetic deafness (Orphanet:87884)

HPO phenotypes

3 total (4 of 3 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000365	Hearing impairment
HP:0003577	Congenital onset
HP:0000717	Autism

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010002_241	Refractive error	3.000000e-13

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500
D034381	Hearing Loss	C09.218.458.341; C10.597.751.418.341; C23.888.592.763.393.341
C564609	Deafness, Autosomal Recessive (supp.)
C580334	Nonsyndromic Deafness (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation	2
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol S	decreases methylation	1
Rotenone	decreases expression	1
Valproic Acid	increases methylation	1

Clinical trials (associated diseases)

301 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00205881	PHASE4	COMPLETED	Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System
NCT00331539	PHASE4	UNKNOWN	Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant
NCT00424307	PHASE4	UNKNOWN	Bilateral Cochlear Implant Benefit in Young Children
NCT00765635	PHASE4	COMPLETED	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal
NCT03321006	PHASE4	COMPLETED	Treating Hearing Loss to Improve Mood and Cognition in Older Adults
NCT01499901	PHASE3	WITHDRAWN	Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children
NCT02561091	PHASE3	COMPLETED	AM-111 in the Treatment of Acute Inner Ear Hearing Loss
NCT03331627	PHASE3	COMPLETED	Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL
NCT05532657	PHASE3	ACTIVE_NOT_RECRUITING	ACHIEVE Brain Health Follow-Up Study
NCT00013455	PHASE2	COMPLETED	Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting
NCT00323427	PHASE2	COMPLETED	Clinical Trial of the Living Well With Hearing Loss Workshop
NCT00552786	PHASE2	COMPLETED	Antioxidation Medication for Noise-induced Hearing Loss
NCT00802425	PHASE2	COMPLETED	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
NCT01139281	PHASE2	COMPLETED	The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
NCT01451853	PHASE2	UNKNOWN	SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
NCT01588925	PHASE2	COMPLETED	Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT02832128	PHASE2	COMPLETED	Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
NCT04915183	PHASE2	RECRUITING	Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT05258773	PHASE2	COMPLETED	Evaluation of the Presence of SENS-401 in the Perilymph
NCT06340633	PHASE2	RECRUITING	SPI-1005 in Adults Receiving Cochlear Implant
NCT00582946	PHASE1	COMPLETED	Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding
NCT00584155	PHASE1	WITHDRAWN	Protection From Cisplatin Ototoxicity by Lactated Ringers
NCT01206829	PHASE1	UNKNOWN	Hearing Impairment, Cognitive Therapy and Coping
NCT01256229	PHASE1	COMPLETED	Outcomes In Children With Developmental Delay And Deafness
NCT01343394	PHASE1	WITHDRAWN	Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
NCT01452607	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT04041440	PHASE1	COMPLETED	Speech Recognition Training in Children With Hearing Loss
NCT07218913	PHASE1	RECRUITING	Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
NCT01802190	Not specified	TERMINATED	Prevalence of POU4F3 and SLC17A8 Mutations
NCT00486577	PHASE2/PHASE3	COMPLETED	Chronic Electrical Stimulation of the Auditory Cortex for Intractable Tinnitus
NCT00789061	PHASE2/PHASE3	UNKNOWN	Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation
NCT01423409	PHASE2/PHASE3	COMPLETED	Multicenter Trial Assessing an Innovative VAS of Pain Among Deaf People
NCT05786378	PHASE2/PHASE3	UNKNOWN	Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
NCT01108601	PHASE1/PHASE2	UNKNOWN	Transtympanic Ringer’s Lactate for the Prevention of Cisplatin Ototoxicity
NCT01621256	PHASE1/PHASE2	COMPLETED	Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss
NCT06370351	PHASE1/PHASE2	RECRUITING	A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
NCT06545175	PHASE1/PHASE2	RECRUITING	Intracochlear Application of VSF1.01 for the Reduction of Cochlear Implant Surgery Related Trauma
NCT07304024	PHASE1/PHASE2	RECRUITING	A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound